The many facets of stone disease: a practical outlook on 24-hour urine and genetic testing

Ashish M. Kamat, MD, MBBS, provides expert insights into the current state of bladder cancer care, emphasizing the critical role of patient-centric approaches and exploring the evolving treatment landscape. Kamat is an endowed professor of urologic oncology and cancer research at the University of Texas MD Anderson Cancer Center and president of the IBCG (International Bladder Cancer Group) and former president of the IBCN (International Bladder Cancer Network). Dr. Kamat has been compensated by J&J for his time to develop this content.

Neal Shore, MD, FACS, is a U.S. Chief Medical Officer at GenesisCare USA and Medical Director of the Carolina Urologic Research Center. He also was an investigator on the Phase 2 and 3 studies in the clinical trial program for nadofaragene firadenovec-vncg.

Dr. Michael Lipkin discusses a recent study conducted at Duke University Hospital that found that a new single-use cystoscope demonstrated superior flexion and comparable optics to the reusable scopes already being used in a hospital urology department.